Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

FTH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Faeth Therapeutics, Inc.NASDAQ: FTH

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $9.18M rose 262.4% year over year, ahead of the +107.0% change in trailing-twelve-month research & development. Sequentially, it fell 48.9% from the prior quarter. Over 3 fiscal years it compounded at -28.2% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +262.4% holds above the trailing-twelve-month pace of +107.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$9.18M-48.9% QoQ
Last fiscal yearDec 2025
$10.96M-41.2% YoY
LTMJun 2026
$31.84M+107.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+262.4%——
1 year-41.2%——
3-year CAGR-28.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
10.96M USD
Year-over-year change
-41.2%
4-year CAGR
-15.7%

Research & Development vs competitors

How FTH compares with its peers on the latest reported figures

  • FTH's LTM Jun 2026 research & development of $31.84M is the lowest of the 10 companies compared; the peer median is $127.65M.
  • Its year-over-year change of +107.0% is the highest of 10, against a peer median of +18.2%.
  • Over three fiscal years its annual growth of -28.2% compares with a peer median of +7.7%.
FTH Competitors Peer median
Research & Development for FTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLAYRelay Therapeutics, Inc.LTM Jun 2026$270.72M -4.1%+2.0%2615.7%
KURAKura Oncology, Inc.LTM Mar 2026$260.36M +37.3%+39.3%363.4%
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M +14.3%+7.7%—
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M +18.2%+9.4%75.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$127.65M +60.8%+33.1%590.6%
VSTMVerastem, Inc.LTM Mar 2026$123.67M +33.3%+31.4%249.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$68M +23.2%+5.9%29.9%
BOLDBoundless Bio, Inc.LTM Mar 2026$42.44M -21.4%+6.5%—
FTHFaeth Therapeutics, Inc.LTM Jun 2026$31.84M +107.0%-28.2%—
Peer median (excluding FTH) $127.65M+18.2%+7.7%363.4%

Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue685K1.81M571K551K0
Gross Profit(685K)(1.81M)(571K)(551K)0
Gross Margin—————
Research & Development21.66M29.58M18.3M18.63M10.96M
Selling, General & Admin15.14M17.73M18.77M12.49M11.33M
Operating Expenses36.8M47.31M36.49M31.11M22.29M
Depreciation & Amortization685K1.81M3.68M551K139K
EBITDA(35.44M)(46.56M)(33.39M)(29.52M)(20.91M)
EBITDA Margin—————
Operating Income(37.48M)(49.12M)(37.06M)(31.66M)(22.29M)
Operating Margin—————
Interest Income800K1.78M3.62M2.55M1.24M
Interest Expense670K219K144K90K32K
Other Income / Expenses688K532K2.96M1.51M1.2M
Income Before Tax(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Net Margin—————
EPS (Basic)(26.56)(31.65)(24.40)(24.01)(16.72)
EPS (Diluted)(26.56)(31.65)(24.40)(24.01)(16.72)
Weighted Avg Shares1.39M1.54M1.4M1.26M1.26M
Weighted Avg Shares (Diluted)1.39M1.54M1.4M1.26M1.26M

Faeth Therapeutics, Inc.

NASDAQ:FTH

Intrinsic Alpha fair value

Locked

Current Price

$8.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.